Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KBP-5074 in moderate hepatic impairment
NCT04534699Phase 1Completed
- Sponsor
- KBP Biosciences
- Start
- Aug 2020
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ocederenone (2 arms), sponsored by KBP Biosciences. Primary endpoints: Maximum Observed Concentration at 264 hours, Area Under the Concentration-Time Curve from Time 0 to Infinity at 264 hours and 3 more. Started Aug 2020; status: completed.
02
Drugs
ocederenone
Beyond the preview
Go deeper on NCT04534699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04534699.